Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA.

Abstract

Seventy-three patients infected with human immunodeficiency virus type 1 (HIV-1) were enrolled in a prospective observational study to investigate the efficacy and tolerance of substituting a nonnucleoside reverse transcriptase inhibitor (NNRTI) for a protease inhibitor (PI) in patients whose plasma viral load (pVL) was controlled by a PI regimen. After a median follow-up of 52 weeks, 63 patients (86.3%) had undetectable pVLs. The incidence of virological breakthrough at 12 months of follow-up was 6.5% (95% confidence interval [CI], 1-20) among patients who had been antiretroviral naive before receiving HAART and 19.2% (95% CI, 6-34) among patients who had been treated with antiretroviral drugs before receiving the PI regimen (P=.10).

Statistics

02040'03'05'07'09'11'13'15'17
Citations per Year

71 Citations

Semantic Scholar estimates that this publication has 71 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Raffi2000SubstitutionOA, title={Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA.}, author={François Raffi and B{\'e}n{\'e}dicte Bonnet and Virginie Ferr{\'e} and Julien Esnault and Philippe Vande Perre and V{\'e}ronique Reliquet and Sophie L{\'e}autez and C Bouillant and O Vergnoux and Pierre Weinbreck}, journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America}, year={2000}, volume={31 5}, pages={1274-8} }